Generic placeholder image

Current Pharmaceutical Design

Editor-in-Chief

ISSN (Print): 1381-6128
ISSN (Online): 1873-4286

General Review Article

Predictive Value of Methods Measuring Platelet Activation for Ischemic Events in Patients Receiving Clopidogrel: A Systematic Review and Meta-analysis

Author(s): Zhe Wang, Qiufen Xie, Qian Xiang, Yanjun Gong, Jie Jiang and Yimin Cui*

Volume 24 , Issue 44 , 2018

Page: [5313 - 5333] Pages: 21

DOI: 10.2174/1381612825666190206114724

Price: $65

Abstract

This study investigates the efficiency and predictive value of light-transmission aggregometry (LTA), vasodilator-stimulated phosphoprotein (VASP) and VerifyNow for ischemia in patients undergoing percutaneous coronary intervention (PCI). Studies that used LTA, VASP or VerifyNow to predict ischemia were included, and their quality and efficiency were analyzed using Review Manager 5.3. The sensitivity and specificity of subgroup studies based on the outcome, cut-off value, and follow-up days were calculated and the summary ROC (sROC) curves were compared after having been fitted. Thirty-one studies including a total of 17,314 participants were analyzed. LTA, VASP and VerifyNow presented a considerable efficiency in predicting ischemic clinical events. In the subgroup analysis, the sensitivities of LTA, VASP and VerifyNow in predicting cardiac death, all-cause death, myocardial infarction, stent thrombosis, stroke, and revascularization were 0.40/0.63/0.62, 0.47/0.56/0.39, 0.40/0.48/0.60, 0.44/0.58/0.70, 0.29/not applicable/0.60 and 0.44/0.57/0.37, respectively and the specificities of LTA, VASP, and VerifyNow were 0.85/0.48/0.63, 0.73/0.52/0.63, 0.74/0.55/0.64, 0.75/0.47/0.61, 0.72/not applicable/ 0.61, and 0.70/0.47/0.67, respectively. LTA showed a higher sensitivity in predicting the outcomes over six months than those within six months, while VerifyNow prediction sensitivity was found to be higher within six months. Meanwhile, VerifyNow showed no statistically significant higher AUC of sROC in comparison to LTA and VASP in predicting ischemic events in patients undergoing clopidogrel treatment. The cut-off values of LTA, VASP and VerifyNow were suggested to be 56%, 50% and 235 respectively according to our study.

Keywords: LTA, VASP, VerifyNow, ischemic events, ROC, PCI.

[1]
Bellemainappaix A, O’Connor SA, Silvain J, et al. Association of clopidogrel pretreatment with mortality, cardiovascular events, and major bleeding among patients undergoing percutaneous coronary intervention: a systematic review and meta-analysis. JAMA 2012; 308(23): 2507.
[2]
Redfors B, Ben-Yehuda O, Lin SH, et al. Quantifying Ischemic Risk After Percutaneous Coronary Intervention Attributable to High Platelet Reactivity on Clopidogrel (From the Assessment of Dual Antiplatelet Therapy with Drug-Eluting Stents Study). Am J Cardiol 2017; 120(6): 917-23.
[3]
Gurbel PA, Bliden KP, Samara W, et al. Clopidogrel effect on platelet reactivity in patients with stent thrombosis: results of the CREST Study. J Am Coll Cardiol 2005; 46: 1827-32.
[4]
Breet NJ, van Werkum JW, Bouman HJ, et al. Comparison of platelet function tests in predicting clinical outcome in patients undergoing coronary stent implantation. JAMA 2010; 303(8): 754-62.
[5]
Gurbel PA, Antonino MJ, Bliden KP, et al. Platelet reactivity to adenosine diphosphate and long-term ischemic event occurrence following percutaneous coronary intervention: A potential antiplatelet therapeutic target. Platelets 2008; 19(8): 595-603.
[6]
Levin GN, Bates ER, Blankenship JC, et al. 2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention. A report of the American College of Cardiology Foundation/ American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions. J Am Coll Cardiol 2011; 58(24): e44-e122.
[7]
Windecker S, Kolh P, Alfonso F, et al. 2014 ESC/EACTS Gridlines on myocardial revascularization: the task force on myocardial revascularization of the European Society of Cardiology (ESC) developed with the special contribution of the European Association of Percutaneous Cardiovascular Interventions (EAPCI). Eur Heart J 2014; 35(37): 2541-619.
[8]
Gurbel PA, Tantry US. Clopidogrel resistance? Thromb Res 2007; 120: 311-21.
[9]
Schwarz UR, Geiger J, Walter U, Eigenthaler M. Flow cytometry analysis of intracellular VASP phosphorylation for the assessment of activating and inhibitory signal transduction pathways in human platelets--definition and detection of ticlopidine/ clopidogrel effects. Thromb Haemost 1999; 82: 1145-52.
[10]
Gachet C, Aleil B. Testing antiplatelet therapyEur Heart J Suppl 2008. 10 Suppl A: A28-34.
[11]
van Werkum JW, Ca VDS, Seesing TH, ten Berg JM, Hackeng CM. The flow cytometric VASP assay can be used to determine the effectiveness of clopidogrel in patients treated with abciximab. J Thromb Haemost 2007; 5: 881-3.
[12]
Madsen EH, Saw J, Kristensen SR, Schmidt EB, Pittendreigh C, Maurer-Spurej E. Long-term aspirin and clopidogrel response evaluated by light transmission aggregometry, VerifyNow, and thrombelastography in patients undergoing percutaneous coronary intervention. Clin Chem 2010; 56: 839-47.
[13]
Blindt R, Stellbrink K, De TA, et al. The significance of vasodilator-stimulated phosphoprotein for risk stratification of stent thrombosis. Thromb Haemost 2007; 98: 1329-34.
[14]
Breet NJ, Bouman HJ, Werkum JW, et al. First prospective comparison between platelet function tests in prediction of clinical outcome in 1100 patients undergoing coronary stent placement: Do point-of-care platelet function assays predict clinical outcomes in clopi dogrel pretreated patients undergoing elective PCI (POPular study). JAMA 2010; 303(8): 754-62.
[15]
Flechtenmacher N, Kämmerer F, Dittmer R, et al. Clopidogrel resistance in neurovascular stenting: Correlations between light transmission aggregometry, verifynow, and the multiplate. Am J Neuroradiol 2015; 36(10): 1953-8.
[16]
Dahabreh I, Moorthy D, Lamont JL, et al. Testing of CYP2C19 Variants and Platelet Reactivity for Guiding Antiplatelet Treatment.Agency for Healthcare Research and Quality (US) 2013 sep.
[17]
Mingant F, Didier R, Gilard M, et al. Comparison of four methods to assess high-on platelet reactivity under p2y12 receptor inhibitor. Platelets 2018; 29(3): 1.
[18]
Youn YN, Yi G, Lee S, Joo HC, Yoo KJ. Posttreatment platelet reactivity on clopidogrel is associated with the risk of adverse events after off-pump coronary artery bypass. Am Heart J 2014; 167(6): 818-25.
[19]
Tarantini G, Ueshima D, D’Amico G, et al. Efficacy and safety of potent platelet P2Y12 receptor inhibitors in elderly versus nonelderly patients with acute coronary syndrome: A systematic review and meta-analysis. Am Heart J 2018; 195: 78-85.
[20]
Valenti R, Marcucci R, Capodanno D, et al. Residual platelet reactivity to predict long-term clinical outcomes after clopidogrel loading in patients with acute coronary syndromes: comparison of different cutoff values by light transmission aggregometry from the responsiveness to clopidogrel and stent thrombosis 2-acute coronary syndrome (RECLOSE 2-ACS) study. J Thromb Thrombolysis 2015; 40(1): 76-82.
[21]
Marcucci R, Gori AM, Paniccia R, et al. Cardiovascular death and nonfatal myocardial infarction in acute coronary syndrome patients receiving coronary stenting are predicted by residual platelet reactivity to ADP detected by a point-of-care assay: a 12-month follow-up. Circulation 2009; 119(2): 237-42.
[22]
Gurbel PA, Bliden KP, Navickas IA, et al. Adenosine diphosphate-induced platelet-fibrin clot strength: a new thrombelastographic indicator of long-term poststenting ischemic events. Am Heart J 2010; 160(2): 346-54.
[23]
Cuisset T, Frere C, Quilici J, et al. Predictive values of post-treatment adenosine diphosphate-induced aggregation and vasodilator-stimulated phosphoprotein index for stent thrombosis after acute coronary syndrome in clopidogrel-treated patients. Am J Cardiol 2009; 104(8): 1078-82.
[24]
Schäfer A, Flierl U, Kössler J, et al. Early determination of clopidogrel responsiveness by platelet reactivity indexidentifies patients at risk for cardiovascular events after myocardial infarction. Thromb Haemost 2011; 106(1): 141.
[25]
Yang H, Li Y, Jiang Y, Lv X. Thromboelastography for monitoring platelet function in unruptured intracranial aneurysm patients undergoing stent placement. Interv Neuroradiol 2015; 21(1): 61-8.
[26]
Ko YG, Suh JW, Bo HK, et al. Comparison of 2 point-of-care platelet function tests, VerifyNow Assay and Multiple Electrode Platelet Aggregometry, for predicting early clinical outcomes in patients undergoing percutaneous coronary intervention. Am Heart J 2011; 161(2): 383-90.
[27]
Price MJ, Endemann S, Gollapudi RR, et al. Prognostic significance of post-clopidogrel platelet reactivity assessed by a point-of-care assay on thrombotic events after drug-eluting stent implantation. Eur Heart J 2008; 29(8): 992-1000.
[28]
Patti G, Nusca A, Mangiacapra F, Gatto L, D’Ambrosio A, Sciascio GD. Point-of-care measurement of clopidogrel responsiveness predicts clinical outcome in patients undergoing percutaneous coronary intervention results of the ARMYDA-PRO (Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty-Platelet Reactivity Predicts Outcome) study. J Am Coll Cardiol 2008; 52(14): 1128-33.
[29]
Michael A, Gaglia MD Jr, Rebecca TMPH, et al. Correlation between light transmission aggregometry, VerifyNow P2Y12, and VASP-P platelet reactivity assays following percutaneous coronary intervention. J Interv Cardiol 2011; 24(6): 529-34.
[30]
Siller-Matula JM, Delle-Karth G, Lang IM, et al. Phenotyping vs. genotyping for prediction of clopidogrel efficacy and safety: the PEGASUS-PCI study. J Thromb Haemost 2012; 10(4): 529-42.
[31]
Bonello L, Paganelli F, Arpin-Bornet M, et al. Vasodilator-stimulated phosphoprotein phosphorylation analysis prior to percutaneous coronary intervention for exclusion of postprocedural major adverse cardiovascular events. J Thromb Haemost 2007; 5(8): 1630-6.
[32]
Freynhofer MK, Brozovic I, Bruno V, et al. Multiple electrode aggregometry and vasodilator stimulated phosphoprotein-phosphorylation assay in clinical routine for prediction of postprocedural major adverse cardiovascular events. Thromb Haemost 2011; 105(02): 230-9.
[33]
Morel O, El Ghannudi S, Jesel L, et al. Cardiovascular mortality in chronic kidney disease patients undergoing percutaneous coronary intervention is mainly related to impaired P2Y12 inhibition by clopidogrel. J Am Coll Cardiol 2011; 57(4): 399-408.
[34]
El GS, Ohlmann P, Meyer N, et al. Impact of P2Y12 inhibition by clopidogrel on cardiovascular mortality in unselected patients treated by percutaneous coronary angioplasty: a prospective registry. JACC Cardiovasc Interv 2010; 3(6): 648-56.

Rights & Permissions Print Export Cite as
© 2022 Bentham Science Publishers | Privacy Policy